Application of nanocarrier-based drug delivery system in treatment of oral cancer

References

• Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–316.
   PubMed Web of Science ®Google Scholar
• Petersen PE. Oral cancer prevention and control – the approach of the World Health Organization. Oral Oncol. 2009;45:454–460.
   PubMed Web of Science ®Google Scholar
• Cheng YSL, Rees T, Wright J. A review of research on salivary biomarkers for oral cancer detection. Clin Transl Med. 2014;3:3.
   PubMedGoogle Scholar
• Agrawal M, Pandey S. Oral cancer awareness of the general public in Gorakhpur city, India. Asian Pac J Cancer Prev. 2012;13:5195–5199.
   PubMedGoogle Scholar
• Savla R, Ivanova V, Minko T. Nanoparticles in the development of therapeutic cancer vaccines. Pharm Nanotechnol. 2014;2:2–22.
   Google Scholar
• Lauer AC, Ramachandran C, Linda M, et al. Targeted delivery to the pilosebaceous unit via liposomes. Adv Drug Deliv Rev. 1996;18:311–324.
   Web of Science ®Google Scholar
• Heber EM, Hawthorne MF, Kueffer PJ, et al. Therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes for oral cancer in the hamster cheek pouch model. Proc Natl Acad Sci USA. 2014;111:16077–16081.
   PubMed Web of Science ®Google Scholar
• Sankhyan A, Pawar P. Recent trends in niosome as vesicular drug delivery system. J Appl Pharm Sci. 2012;02:20–32.
   Google Scholar
• Alvi IA, Madan J, Kaushik D, et al. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in-vitro release, and cytotoxicity analysis. Anticancer Drugs. 2011;22:774–782.
   PubMed Web of Science ®Google Scholar
• Bayindir ZS, Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci. 2010;99:2049–2060.
   PubMed Web of Science ®Google Scholar
• Calixto G, Bernegossi J, Chorilli M. Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomed. 2014;9:3719–3735.
   PubMed Web of Science ®Google Scholar
• Koch FP, Kunkel M, Biesterfeld S, et al. Diagnostic efficiency of differentiating small cancerous and precancerous lesions using mucosal brush smears of the oral cavity - a prospective and blinded study. Clin Oral Invest. 2010;15:763–769.
   PubMed Web of Science ®Google Scholar
• Gelderblom H. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–1598.
   PubMed Web of Science ®Google Scholar
• Kloover JS, Den Bakker MA, Gelderblom H, et al. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer. 2004;90:304–305.
   PubMed Web of Science ®Google Scholar
• Lu J, Liong M, Sherman S, et al. Mesoporous silica nanoparticles for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells. Nanobiotechnol. 2007;3:89–95.
   PubMedGoogle Scholar
• Kakde D, Jain D, Shrivastava V, et al. Cancer therapeutics - opportunities, challenges and advances in drug delivery. J Appl Pharm Sci. 2011;1:1–10.
   Google Scholar
• Coelho KR. Challenges of the oral cancer burden in India. J Cancer Epidemiol. 2012;2012:701932.
   PubMedGoogle Scholar
• Sutradhar KB, Amin L. Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnol. 2014;2014:939378.
   Google Scholar
• Mathur M, Sundaramoorthy S. Anticancer herbal drugs and their improvement through novel drug delivery approaches. Appl Biol Res. 2013;15:1–20.
   Google Scholar
• Werner JA, Rathcke IO, Mandic R. The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis. 2002;19:275–282.
   PubMed Web of Science ®Google Scholar
• Zhang J, Lan CQ, Post M. Design of nanoparticles as drug carriers for cancer therapy. Cancer Genom Proteom. 2006;3:147–158.
   PubMedGoogle Scholar
• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631–651.
   PubMed Web of Science ®Google Scholar
• Nie S, Xing Y, Kim GJ. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9:257–288.
   PubMed Web of Science ®Google Scholar
• Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci. 1996;85:1142–1168.
   PubMed Web of Science ®Google Scholar
• Vyas A, Saraf S. Cyclodextrin based novel drug delivery systems. J Incl Phenom Macrocycl Chem. 2008;62:23–42.
   Web of Science ®Google Scholar
• Szente L, Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Deliv Rev. 1999;36:17–28.
   PubMed Web of Science ®Google Scholar
• Moorthi C, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci. 2011;14:67– 77.
   PubMed Web of Science ®Google Scholar
• Bilensoy E, Gurkaynak O, Ertan M, et al. Development of non-surfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci. 2008;97:1519–1529.
   PubMed Web of Science ®Google Scholar
• Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer. 2008;99:392–397.
   PubMed Web of Science ®Google Scholar
• Balaji A, Pandey VP, Srinath MS, et al. Synthesis and characterization studies of cisplatin/hydroxypropyl-β-cyclodextrin complex. Pharmacologyonline. 2009;1:1135–1143.
   Google Scholar
• Agueros M, Ruiz-Gaton L, Vauthier C, et al. Combined hydroxypropyl-β-cyclodextrin and poly (anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci. 2009;38:405–413.
   PubMed Web of Science ®Google Scholar
• Huang XX, Zhou CL, Wang H, et al. Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex. AAPS PharmSciTech. 2011;12:665–672.
   PubMed Web of Science ®Google Scholar
• Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310–1316.
   PubMed Web of Science ®Google Scholar
• Oommen E, Tiwari SB, Udupa N, et al. Niosome entrapped β- cyclodextrin methotrexate complex as a drug delivery system. Indian J Pharmacol. 1999;31:279–284.
   Google Scholar
• Kavitha K, Srinivasa RA, Nalini CN. An investigation on enhancement of solubility of 5-fluorouracil by applying complexation technique - characterization, dissolution and molecular-modeling studies. J Applied Pharm Sci. 2013;3:162–166.
   Google Scholar
• Shrikhande S, Bajaj AN, Malhotra G, et al., inventors. Cipla Limited, King, Lawrence, assignee. Pharmaceutical compositions of polymeric nanoparticles. WO2016020697 A1. 2016 Feb 11.
   Google Scholar
• Lee SJ, Kim YH, Lee SH, et al., inventors. JW Pharmaceutical Corporation, assignee. Oxaliplatin nanoparticles and method for preparing same. US9393201 B2. 2016 Jul 19.
   Google Scholar
• Thaxton SC, Gordon LI, Mutharasan RK, et al., inventors. Northwestern University, assignee. Lipophilic nanoparticles for drug delivery. WO2015023797 A9. 2015 Mar 7.
   Google Scholar
• Severin E, Zykova I, Gulenko, V, et al., inventors. Unichempharm Ltd, Oy Filana Ltd, assignee. Docetaxel-based prolonged-release cancer treatment drug. US20150140109 A1. 2015 May 21.
   Google Scholar
• Braden ARC, Vishwanatha JK, inventors. University of North Texas Health Science Center at Fort Worth, assignee. Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics. US9023395 B2. 2015 May 5.
   Google Scholar
• Desai NP, Shiong PS, Trieu V, inventors. Abraxis Bioscience, LLC, Los Angeles, CA, USA, assignee. Nanoparticle comprising rapamycin and albumin as anticancer agent. US 8,911,786 B2. 2014 Dec 16.
   Google Scholar
• Messersmith PB, Black KCL IV, Yi L, et al., inventors. Northwestern University, assignee. Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same. US8784895 B2. 2014 Jul 22.
   Google Scholar
• Severin E, Zykova I, Gulenko V, inventors. Oy Filana Ltd, assignee. Docetaxel-based prolonged-release cancertreatment drug. WO2013171382 A1. 2013 Nov 21.
   Google Scholar
• Maitra A, Pramanik D, inventors. The Johns Hopkins University, assignee. Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity. EP2648760 A2. 2013 Oct 16.
   Google Scholar
• Dash AK, Trickler WJ, inventors. Creighton University, assignee. Mucoadhesive nanoparticles for cancer treatment. US8242165 B2. 2012 Aug 14.
   Google Scholar
• Lee SJ, Kim YH, Lee SH, et al., inventors. Choongwae Pharma Corporation, assignee. Oxaliplatin nanoparticles and method for preparing same. WO2011034394 A2. 2011 Mar 24.
   Google Scholar
• Hong SH, Chung JH, inventors. Water-soluble organometallic nanoparticles and method for preparing the same. WO2007108618 A1. 2007 Sep 27.
   Google Scholar
• Nah JW, Jung TR, Chae SY, et al., inventors. Anti-cancer agent loaded hydrophobic bile acid conjugated hydrophilic chitosan oligosaccharide nanoparticles and preparation method thereof. WO2007086651 A1. 2007 Aug 2.
   Google Scholar
• Prasad NP, Roy I, Bergey EJ, et al., inventors. The Research Foundation of State University of New York, assignee. Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same. CA 2513759 A1. 2004 Aug 12.
   Google Scholar
• Liversidge GG, Liversidge E, Chester W, et al., inventors. Eastman Kodak Company, Rochester, NY, assignee. Surface modified anticancer nanoparticles. 1995. US005399363A.
   Google Scholar
• Hallan SS, Kaur P, Kaur V, et al. Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery. Artif Cells Nanomed Biotechnol. 2014;44:334–349.
   PubMed Web of Science ®Google Scholar